When you linking your Twitter Account Market Wire News Trending Stocks news and your Portfolio Stocks News will automatically tweet from your Twitter account.
Be alerted of any news about your stocks and see what other stocks are trending.
IO Biotech (NASDAQ:IOBT) has begun a phase 2 trial of its non-small cell lung cancer candidate IO102-IO103. In the trial, the candidate will be combined with Merck's (MRK) Keytruda (pembrolizumab) in a first-line setting. The trial will also examine the combination in patients with squamous cell carcinoma of the head and neck and urothelial bladder cancer. IO Biotech recently released phase 1/2 data on IO102-IO103 for metastatic melanoma.